Gemcitabine doublets in advanced urothelial cancer

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 3, 2002, Pages 15-19

  Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR INHIBITOR; EPIRUBICIN; GEMCITABINE; METHOTREXATE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; HUMAN; METASTASIS; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR;

EID: 0036125648     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30752     Document Type: Conference Paper

References (37)

1. Gemcitabine in locally advanced and/or metastatic bladder cancer
2. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
3. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium
4. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
5. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
6. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
7. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
8. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
9. Sample sizes for event rate equivalence trials using prior information
10. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma
11. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study
12. Treatment of metastatic urothelial cancer in the post-MVAC era
13. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma (TCC) of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network
14. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2W): A multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC)
15. Second-line chemotherapy with every 2-week gemcitabine and paclitaxel in previously treated patients with transitional cell carcinoma
16. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma
17. A phase I trial of docetaxel and gemcitabine in patients with advanced cancer
18. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor
19. Adriamycin in advanced urinary tract cancer: Experience in 42 patients and review of the literature
20. Sequential doxorubicin/gemcitabine (AG) and ifosfamide, paclitaxel, and cisplatin (ITP) chemotherapy (AG-1TP) in patients (Pts) with metastatic or locally advanced transitional cell carcinoma of the urothelium (TCC)
21. The Norton-Simon hypothesis revisited
22. Invasion of the bladder by transitional cell carcinoma: Its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2
23. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
24. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
25. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
26. Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr), for patients (Pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens
27. Analysis of HER2/neu overexpression in primary and metastatic transitional cell carcinoma of the bladder
28. Heterogeneity of erbB-2 gene amplification in bladder cancer
29. Can HER2 status predict response to cancer therapy?
30. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
31. Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder
32. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
33. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
34. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group
35. Phase II trial of gemcitabine plus carboplatin for urothelial transitional cell carcinoma in advanced or metastic stage
36. Palliative chemotherapy with gemcitabine (Gem) and carboplatin (CBDCA) in advanced transitional cell carcinoma of the urothelium (ATCCU): Preliminary results
37. A dose finding study of carboplatin with fixed doses of gemcitabine in "unfit" patients with advanced bladder cancer